Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Eli Lilly and Company
Genzada Pharmaceuticals USA, Inc.
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)